Prior investigations have reported that changes in the prefrontal electroencephalogram (EEG) precede symptom improvement from antidepressant medications, and could serve as a biomarker of treatment outcome in major depressive disorder (MDD). A new physiologically defined region of interest (ROI), overlying the midline and right frontal (MRF) cortical area, was examined here for a relationship between early decreases in theta-band cordance and remission. Subjects were 72 adults with unipolar MDD who had completed placebo-controlled antidepressant treatment trials, with 37 randomized to medication and 35 to placebo. We assessed changes in cordance and absolute and relative power in the MRF region at 48 h, 1 week, and 2 weeks after start of drug, as potential predictors of remission (final score on the 17-item Hamilton Depression Rating Scale of 5 or below. Out of 37 medication-treated subjects, 11 (30%) remitted versus 6 of 35 placebo subjects (17%). Change in MRF cordance 1 and 2 weeks after the beginning of treatment was significantly associated with remission in medication-treated subjects at 1 week, with receiver operating characteristic (ROC) analysis yielding 0.76 area under the curve. Decreases in MRF cordance at 1 week predicted remission with medication with 69% overall accuracy (90% sensitivity; 60% specificity). MRF cordance changes were not associated with remission with placebo. Absolute and relative power did not differentiate groups. These results suggest that remission may be predictable from physiologic measurements after 1 week of treatment, and that this region merits further investigation in the neurobiology of treatment response.
Introduction
Achievement of remission has been identified as the key objective for the treatment of major depressive disorder (MDD) (cf. Nierenberg and Wright, 1999; cf. Keller, 2004) . Although some 85-90% of patients can eventually experience symptomatic improvement with antidepressant medications, attaining this objective remains elusive. In the STAR⁎D effectiveness study of "real world" patients with MDD ("Sequenced Treatment Alternative to Relieve Depression" http://star-d.org), less than a third achieved remission with the first antidepressant trial, despite aggressive dosing, close measurement-based monitoring, and a 12-week period to exhibit improvement (Trivedi et al., 2006a) ; at the end of a second level of randomized treatment, the total fraction of remitted subjects was approximately 50%, leaving almost half of subjects with incomplete responses (Rush et al., 2006; Trivedi et al., 2006b ). Ominously, patients who do not achieve remission suffer not only ongoing symptoms, but also persistent impairments in psychosocial function (Miller et al.,1998; Papakostas et al., 2004) , functional disability at work and home (Mojtabai, 2001; Ormel et al., 2004; Vos et al., 2004) , and increased rates of relapse (Paykel et al., 1995; Judd et al., 1998; Nierenberg and Wright, 1999) . In a comparison of long-term outcomes for individuals who entered follow-up after an acute course of treatment either with or without residual symptoms, Paykel et al. (1995) found that 76% of subjects who entered follow-up with residual symptoms (i.e., response but not remission) had relapsed by 15 months versus only 25% of those who had experienced an initial remission, giving added clinical significance to this distinction in outcome threshold. Means to achieve remission have been the focus of large-scale investigations. Algorithm-based approaches, such as studied in the TMAP ("Texas Medication Algorithm Project", Rush et al.,1999; Trivedi et al., 2000) and STAR⁎D trials, provide an evidence base for selecting subsequent treatments, but these decisions are made for individual patients only after a remission has failed to occur despite an adequate trial of a particular intervention, a process which takes weeks to months for each sequential trial. The duration of algorithm-based treatment could be shortened if practitioners could identify, early in a treatment phase, those individuals who are unlikely to remit, and institute different, augmented, and/or more complex treatments sooner for those patients who need them. 
